255 related articles for article (PubMed ID: 27462021)
1. Designer interface peptide grafts target estrogen receptor alpha dimerization.
Chakraborty S; Asare BK; Biswas PK; Rajnarayanan RV
Biochem Biophys Res Commun; 2016 Sep; 478(1):116-122. PubMed ID: 27462021
[TBL] [Abstract][Full Text] [Related]
2. In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface.
Chakraborty S; Cole S; Rader N; King C; Rajnarayanan R; Biswas PK
Mol Divers; 2012 Aug; 16(3):441-51. PubMed ID: 22752657
[TBL] [Abstract][Full Text] [Related]
3. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
4. Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.
Lee DH; Asare BK; Rajnarayanan RV
Cell Cycle; 2016 Oct; 15(20):2806-18. PubMed ID: 27580430
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
6. In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA).
Iwabuchi E; Miki Y; Ono K; Onodera Y; Suzuki T; Hirakawa H; Ishida T; Ohuchi N; Sasano H
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):159-169. PubMed ID: 27264933
[TBL] [Abstract][Full Text] [Related]
7. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.
Trauernicht AM; Kim SJ; Kim NH; Boyer TG
Mol Endocrinol; 2007 Jul; 21(7):1526-36. PubMed ID: 17473282
[TBL] [Abstract][Full Text] [Related]
8. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
9. Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.
Asare BK; Yawson E; Rajnarayanan RV
Cell Cycle; 2017 Aug; 16(15):1465-1477. PubMed ID: 28723234
[TBL] [Abstract][Full Text] [Related]
10. Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.
De Vries-van Leeuwen IJ; da Costa Pereira D; Flach KD; Piersma SR; Haase C; Bier D; Yalcin Z; Michalides R; Feenstra KA; Jiménez CR; de Greef TF; Brunsveld L; Ottmann C; Zwart W; de Boer AH
Proc Natl Acad Sci U S A; 2013 May; 110(22):8894-9. PubMed ID: 23676274
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
13. Coumarin-Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer.
Selvaraj J; John JBA; Joghee NM; Antony J; Wadhwani A; Natarajan J
Anticancer Agents Med Chem; 2020; 20(4):437-449. PubMed ID: 31746305
[TBL] [Abstract][Full Text] [Related]
14. Proteomic identification of Profilin1 as a corepressor of estrogen receptor alpha in MCF7 breast cancer cells.
Kanaujiya JK; Lochab S; Kapoor I; Pal P; Datta D; Bhatt ML; Sanyal S; Behre G; Trivedi AK
Proteomics; 2013 Jul; 13(14):2100-12. PubMed ID: 23576398
[TBL] [Abstract][Full Text] [Related]
15. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
16. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
18. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth.
DeNardo DG; Cuba VL; Kim H; Wu K; Lee AV; Brown PH
Mol Cell Endocrinol; 2007 Oct; 277(1-2):13-25. PubMed ID: 17825481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
